AEBi
Therapeutic Peptides for Personalized Cancer Treatment
Company Overview
Snapshot
Founded in June 2000 by Ilan Morad, AEBi operates with 1–10 employees. The company is engaged in the discovery and development of therapeutic peptides, holding a patent for its combinatorial biology screening platform technology.
Business overview
AEBi (Accelerated Evolution Biotechnologies) is a development-stage biopharmaceutical company focused on the discovery and development of therapeutic peptides. The company utilizes an IP-protected combinatorial biology screening platform technology to identify binders to known targets and select functional molecules. AEBi's platform is designed for flexibility, leveraging combinatorial biology to discover new and improved lead compounds for disease targets, primarily serving the biopharmaceutical and pharmaceutical industries within the Health Tech & Life Sciences sector.
Strategic signal
In January 2019, AEBi garnered significant media attention regarding its claims of developing a cancer cure. While the company stated it could not afford to publish findings, the news generated both interest and skepticism within the scientific community, highlighting the high-stakes and often controversial nature of breakthrough claims in cancer research.
Log in to access full profile ›Company Intelligence Q&A
- What is AEBi's core technology?
- AEBi has developed an IP-protected combinatorial biology screening platform technology. This platform is designed to discover new and better lead compounds to disease targets by finding binders to known targets and selecting the most functional molecules.
- When was AEBi founded and by whom?
- AEBi was founded in June 2000 by Ilan Morad, who also serves as the CEO.
- What is the primary focus of AEBi's research and development?
- AEBi is a development-stage biopharmaceutical company engaged in the discovery and development of therapeutic peptides for personalized cancer treatment.
- Where is AEBi headquartered?
- AEBi is headquartered in Ness Ziona, Israel, and was incorporated at the Weizmann Institute's ITEK technological incubator.
- Has AEBi engaged in any notable collaborations?
- AEBi has a collaboration agreement with the Israeli biopharmaceutical company Proteologics.